| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 702.52 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Introdução: A Insuficiência Cardíaca é uma patologia crónica que nos últimos anos tem
vindo a aumentar o seu impacto nas sociedades a nível global, estando intimamente
relacionada com a Hiponatremia, que é considerada um fator preditor de mau
prognóstico. Com esta revisão bibliográfica pretende-se perceber qual o impacto dos
Antagonistas Seletivos dos Recetores da Vasopressina na correção da Hiponatremia na
Insuficiência Cardíaca, em comparação com as terapêuticas mais convencionais.
Métodos: Pesquisa de artigos no motor de busca Pubmed, em língua inglesa e
portuguesa, sem restrição de data de publicação, utilizando os termos: “Heart failure”;
“Hyponatremia”; “Selective Vasopressin Receptor Antagonists”; “Tolvaptan”.
Resultados: A interpretação da bibliografia de base demonstrou que ainda existe um
certo grau de incapacidade na correção da Hiponatremia, apesar das diversas técnicas já
existentes na atualidade. Os Antagonistas Seletivos dos Recetores da Vasopressina,
nomeadamente o Tolvaptan, demonstraram ser capazes de corrigir a Hiponatremia em
situações agudas, tendo demonstrado, em determinados estudos, resultados superiores
comparativamente a outras técnicas como soluções salinas hipertónicas e diuréticos. No
entanto, ainda não foi estabelecido qual o real impacto destes fármacos a longo prazo na
Insuficiência Cardíaca.
Conclusão: Perante os resultados obtidos, os Antagonistas Seletivos dos Recetores da
Vasopressina podem vir a desempenhar um papel com maior importância no tratamento
agudo da Hiponatremia presente na Insuficiência Cardíaca, apesar das diversas
terapêuticas convencionais já existentes. No entanto, é essencial promover estudos de
maior duração para investigar o impacto a longo prazo destes fármacos no
desenvolvimento da Insuficiência Cardíaca.
Introduction: Heart Failure is a chronic disease that has recently increased its impact on societies globally in recent years, being closely related to hyponatremia, which is considered a predictor of poor prognosis. This bibliographic review aims to understand the impact of Selective Vasopressin Receptor Antagonists in the correction of Hyponatremia in Heart Failure, in comparison with more conventional therapies. Material and methods: Search and analysis of English and Portuguese articles on PubMed search engine, without publication date restriction, using the terms: “Heart failure”; "Hyponatremia"; "Selective Vasopressin receptor antagonists"; "Tolvaptan". Results: The interpretation of the basic bibliography demonstrated that there is still a certain degree of inability to correct Hyponatremia, despite the current techniques that already exist. Selective Vasopressin Receptor Antagonists, and in particular Tolvaptan, demonstrated to be able to correct Hyponatremia in acute situations, having demonstrated, in certain studies, superior results when compared to other techniques such as hypertonic saline solutions and diuretics. However, the real impact of these drugs in Heart Failure has not been established yet. Conclusions: According to the obtained results, Vasopressin Receptor Antagonists may come to play a more important role in the acute treatment of Hyponatremia present in Heart Failure, despite the various conventional therapies that already exist. However, it is essential to promote longer studies to investigate the long-term impact of these drugs on the development of Heart Failure.
Introduction: Heart Failure is a chronic disease that has recently increased its impact on societies globally in recent years, being closely related to hyponatremia, which is considered a predictor of poor prognosis. This bibliographic review aims to understand the impact of Selective Vasopressin Receptor Antagonists in the correction of Hyponatremia in Heart Failure, in comparison with more conventional therapies. Material and methods: Search and analysis of English and Portuguese articles on PubMed search engine, without publication date restriction, using the terms: “Heart failure”; "Hyponatremia"; "Selective Vasopressin receptor antagonists"; "Tolvaptan". Results: The interpretation of the basic bibliography demonstrated that there is still a certain degree of inability to correct Hyponatremia, despite the current techniques that already exist. Selective Vasopressin Receptor Antagonists, and in particular Tolvaptan, demonstrated to be able to correct Hyponatremia in acute situations, having demonstrated, in certain studies, superior results when compared to other techniques such as hypertonic saline solutions and diuretics. However, the real impact of these drugs in Heart Failure has not been established yet. Conclusions: According to the obtained results, Vasopressin Receptor Antagonists may come to play a more important role in the acute treatment of Hyponatremia present in Heart Failure, despite the various conventional therapies that already exist. However, it is essential to promote longer studies to investigate the long-term impact of these drugs on the development of Heart Failure.
Description
Keywords
Antagonistas Seletivos dos Recetores da Vasopressina Hiponatremia Insuficiência Cardíaca Tolvaptan Tratamento